TY - JOUR
T1 - Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout
AU - Bursill, David
AU - Taylor, William J.
AU - Terkeltaub, Robert
AU - Kuwabara, Masanari
AU - Merriman, Tony R.
AU - Grainger, Rebecca
AU - Pineda, Carlos
AU - Louthrenoo, Worawit
AU - Edwards, N. Lawrence
AU - Andrés, Mariano
AU - Vargas-Santos, Ana Beatriz
AU - Roddy, Edward
AU - Pascart, Tristan
AU - Lin, Ching Tsai
AU - Perez-Ruiz, Fernando
AU - Tedeschi, Sara K.
AU - Kim, Seoyoung C.
AU - Harrold, Leslie R.
AU - McCarthy, Geraldine
AU - Kumar, Nitin
AU - Chapman, Peter T
AU - Tausche, Anne Kathrin
AU - Vazquez-Mellado, Janitzia
AU - Gutierrez, Marwin
AU - da Rocha Castelar-Pinheiro, Geraldo
AU - Richette, Pascal
AU - Pascual, Eliseo
AU - Fisher, Mark C.
AU - Burgos-Vargas, Ruben
AU - Robinson, Philip C.
AU - Singh, Jasvinder A.
AU - Jansen, Tim L.
AU - Saag, Kenneth G.
AU - Slot, Ole
AU - Uhlig, Tillmann
AU - Solomon, Daniel H.
AU - Keenan, Robert T.
AU - Scire, Carlo Alberto
AU - Biernat-Kaluza, Edyta
AU - Dehlin, Mats
AU - Nuki, George
AU - Schlesinger, Naomi
AU - Janssen, Matthijs
AU - Stamp, Lisa K.
AU - Sivera, Francisca
AU - Reginato, Anthony M.
AU - Jacobsson, Lennart
AU - Lioté, Frédéric
AU - Ea, Hang Korng
AU - Rosenthal, Ann
AU - Bardin, Thomas
AU - Choi, Hyon K.
AU - Hershfield, Michael S.
AU - Czegley, Christine
AU - Choi, Sung Jae
AU - Dalbeth, Nicola
N1 - Funding Information:
and 阀talian Society for Rheumatology, Milan, 阀ta33lEyd; yta Biernat-Kaluza, PhD: ORL 阀K, Warsaw, Poland; 34Mats Dehlin, MD, PhD, Lennart Jacobsson, MD, PhD: Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 35George Nuki, MBBS: University of Edinburgh, Edinburgh, UK; 36Naomi Schlesinger, MD: Rutgers–Robert Wood Johnson Medical School, Piscataway, New Jersey; 37Lisa K. Stamp, MBChB, PhD: University of Otago, Christchurch, New Zealand; 38Francisca Sivera, MD, PhD: Hospital General Universitario de Elda, Alicante, Spain; 39Anthony M. Reginato, MD, PhD: Warren Alpert School of Medicine at Brown University, Providence, Rhode 阀sland40;A nn Rosenthal, MD: Medical College of Wisconsin and the Clement J. Zablocki Veterans A 贀airs Medical Center, Milwaukee; 41Michael S. Hershfield, MD: Duke University Medical Center, Durham, North Carolina; 42Christine Czegley, MSc: Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; 43Sung Jae Choi, MD, PhD: University of California, San Diego, and Korea University Ansan Hospital, Ansan, South Korea; 44Nicola Dalbeth, MD: University of Auckland, Auckland, New Zealand. Dr. Taylor has received honoraria from Pfizer New Zealand (less than $10,000). Dr. Terkeltaub has received research support from Ardea/Astra-Zeneca and 阀ronwood, and consulting fees from SOB 阀, Kowa, Horizon, and Relburn (less than $10,000 each), and from Selecta (more than $10,000). Dr. Merriman has received research funding and consulting fees from Ardea Biosciences and consulting fees from Horizon (less than $10,000 each). Dr. Grainger has received speaking fees from AbbVie, Pfizer, and Janssen (less than $10,000 each) and a research grant from AbbVie. Dr. Louthrenoo has received speaking and/or consulting fees from Astellas Pharma and speaking fees from American Taiwan Biopharm (less than $10,000 each). Dr. Edwards has received consulting fees from Horizon, 阀ronwood, and Takeda (less than $10,000 each). Dr. Andrés has received consulting fees from AstraZeneca, Grünenthal, and Horizon (less than $10,000 each). Dr. Pascart has received consulting fees from 阀psen Pharma and Mayoly Spindler (less than $10,000 each). Dr. Perez-Ruiz has received speaking and/or consulting fees from Amgen, Ardea Biosciences, AstraZeneca, Faes Farma, Menarini, Horizon, and Pharmaceutical Laboratories ROV 阀 (less than $10,000 each),
Funding Information:
$10,000). Dr. Dehlin has received consulting fees from Grünenthal (less than $10,000). Dr. Nuki has received consulting fees from Grünenthal, Menarini, Savient, and Ardea/AstraZeneca (less than $10,000 each). Dr. Schlesinger has received grants from AstraZeneca, and has received consulting fees from Celgene, AstraZeneca, Horizon, SOB 阀, and Bristol-Myers Squibb (less than $10,000 each). Dr. Janssen has received speaking fees from Grünenthal (less than $10,000). Dr. Stamp has received grants from Ardea Biosciences and has received speaking fees from Amgen (less than $10,000). Dr. Sivera has received speaking and/or consulting fees from Ardea, AstraZeneca, Grünenthal, 阀psen Pharma, Menarini, Novartis, 阀psen Pharma, and Mayoly-Spindler (less than $10,000 each), and has received research grants from Ardea, AstraZeneca, Grünenthal, 阀psen Pharma, Mayoly-Spindler, Menarini, Novartis, and SOB 阀. Dr. Jacobsson has received speaking and/or consulting fees from AbbVie, Novartis, and Eli Lilly (less than $10,000 each). Dr. Lioté has received consulting fees from Ardea, AstraZeneca, Grünenthal, 阀psen Pharma, Menarini, and Novartis (less than $10,000 each), and has received research grants from Ardea, AstraZeneca, Grünenthal, 阀psen Pharma, Mayoly-Spindler, Menarini, Novartis, and SOB 阀. Dr. Bardin has received research grants from AstraZeneca, 阀psen, and Menarini and has received speaking and/or consulting fees from Ampel BioSolutions, Astellas, AstraZeneca, Biomex, Grünenthal, 阀psen, Menarini, Novartis, Savient, and SOB 阀 (less than $10,000 each). Dr. Choi has received consulting fees from Ardea/AstraZeneca and Takeda (less than $10,000 each). Dr. Hershfield receives royalties from Horizon as a co-inventor of pegloticase (Krystexxa). Dr. Dalbeth has received speaking and/or consulting fees or grants from Kowa, Horizon, Takeda, Menarini, Teijin, Amgen, Pfizer, Ardea Biosciences, AstraZeneca, and Cymabay (less than $10,000 each). Address correspondence to Nicola Dalbeth, Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand. E-mail: n.dalbeth@auckland.ac.nz. Submitted for publication December 10, 2017; accepted in revised form May 22, 2018.
Funding Information:
MD, PhD: Toranomon Hospital, Tokyo, Japan, and University of Colorado Denver, Aurora; 5Tony R. Merriman, PhD: University of Otago, Dunedin, New Zealand; 6Carlos Pineda, MD, PhD: 阀nstituto Nacional Rehabilitación Luis Guillermo 阀barra 阀barra, Mexico City, Mexi7cWo;o rawit Louthrenoo, MD: Chiang Mai University, Chiang Mai, Thailand; 8N. Lawrence Edwards, MD, MPH: University of Florida College of Medicine, Gainesville; 9Mariano Andrés, MD, Eliseo Pascual, MD, PhD: Hospital Universitario de Alicante and Universidad Miguel Hernández, Alicante, Spain; 10Ana Beatriz Vargas-Santos, G-CAN was supported by 阀ronwood Pharmaceuticals, Horizon Pharmaceuticals, SOB 阀, Takeda, Teijin, Selecta, and CymaBay.
Publisher Copyright:
© 2018, American College of Rheumatology
PY - 2019/3
Y1 - 2019/3
N2 - Objective: The language currently used to describe gout lacks standardization. The aim of this project was to develop a consensus statement on the labels and definitions used to describe the basic disease elements of gout. Methods: Experts in gout (n = 130) were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach consensus on the labeling and definitions for the basic disease elements of gout. Disease elements and labels in current use were derived from a content analysis of the contemporary medical literature, and the results of this analysis were used for item selection in the Delphi exercise and face-to-face consensus meeting. Results: There were 51 respondents to the Delphi exercise and 30 attendees at the face-to-face meeting. Consensus agreement (≥80%) was achieved for the labels of 8 disease elements through the Delphi exercise; the remaining 3 labels reached consensus agreement through the face-to-face consensus meeting. The agreed labels were monosodium urate crystals, urate, hyperuric(a)emia, tophus, subcutaneous tophus, gout flare, intercritical gout, chronic gouty arthritis, imaging evidence of monosodium urate crystal deposition, gouty bone erosion, and podagra. Participants at the face-to-face meeting achieved consensus agreement for the definitions of all 11 elements and a recommendation that the label “chronic gout” should not be used. Conclusion: Consensus agreement was achieved for the labels and definitions of 11 elements representing the fundamental components of gout etiology, pathophysiology, and clinical presentation. The Gout, Hyperuricemia, and Crystal-Associated Disease Network recommends the use of these labels when describing the basic disease elements of gout.
AB - Objective: The language currently used to describe gout lacks standardization. The aim of this project was to develop a consensus statement on the labels and definitions used to describe the basic disease elements of gout. Methods: Experts in gout (n = 130) were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach consensus on the labeling and definitions for the basic disease elements of gout. Disease elements and labels in current use were derived from a content analysis of the contemporary medical literature, and the results of this analysis were used for item selection in the Delphi exercise and face-to-face consensus meeting. Results: There were 51 respondents to the Delphi exercise and 30 attendees at the face-to-face meeting. Consensus agreement (≥80%) was achieved for the labels of 8 disease elements through the Delphi exercise; the remaining 3 labels reached consensus agreement through the face-to-face consensus meeting. The agreed labels were monosodium urate crystals, urate, hyperuric(a)emia, tophus, subcutaneous tophus, gout flare, intercritical gout, chronic gouty arthritis, imaging evidence of monosodium urate crystal deposition, gouty bone erosion, and podagra. Participants at the face-to-face meeting achieved consensus agreement for the definitions of all 11 elements and a recommendation that the label “chronic gout” should not be used. Conclusion: Consensus agreement was achieved for the labels and definitions of 11 elements representing the fundamental components of gout etiology, pathophysiology, and clinical presentation. The Gout, Hyperuricemia, and Crystal-Associated Disease Network recommends the use of these labels when describing the basic disease elements of gout.
UR - http://www.scopus.com/inward/record.url?scp=85053427249&partnerID=8YFLogxK
U2 - 10.1002/acr.23607
DO - 10.1002/acr.23607
M3 - Article
C2 - 29799677
AN - SCOPUS:85053427249
SN - 2151-464X
VL - 71
SP - 427
EP - 434
JO - Arthritis Care and Research
JF - Arthritis Care and Research
IS - 3
ER -